To explore the mechanism of Danhong Injection (丹红注射液) in the treatment of the patients with acute cerebral infarction through the stromal cell-derived factor-1 (SDF-1)/CXC chemokine receptor-4 (CXCR4) signaling pathway.

A total of 104 patients with acute cerebral infarction admitted to Tianjin Fourth Central Hospital from March 2024 to March 2025 were selected. A single-center randomized double-blind controlled trial design was adopted, and they were divided into the control group and the observation group by the random number table method, with 52 cases in each group. The control group was given alteplase, and the observation group was treated with Danhong Injection on the basis of the treatment of the control group. Both groups were given symptomatic treatment for one 10 consecutive days. After 10 days of treatment, the SDF-1/CXCR4 signaling pathways and modified Rankin scale (mRS) scores of the two groups before and after treatment were compared, and the therapeutic effects and adverse reactions of the two groups were recorded.

The total effective rate of the observation group was 98.08%, which was higher than that (86.54%) of the control group (P<0.05). Before treatment, the levels of SDF-1 and CXCR4 in the two groups were not significant (P>0.05). After the treatment, the levels of SDF-1 and CXCR4 in the observation group were lower than those in the control group (P<0.05). Before treatment, the mRS scores of the two groups were not significant (P>0.05). After the treatment, the mRS score of the observation group was lower than that of the control group (P<0.05).

Danhong Injection can exert its therapeutic effect on acute cerebral infarction through the SDF-1/CXCR4 signaling pathway, with obvious curative effect and worthy of clinical promotion and application.